Cargando…

The complexity of microenvironment-mediated drug resistance

Detalles Bibliográficos
Autores principales:	Fedorenko, Inna V., Smalley, Keiran S.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633163/ https://www.ncbi.nlm.nih.gov/pubmed/26622938

Ejemplares similares

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

BRAF inhibition generates a host/tumor niche that mediates therapeutic escape
por: Fedorenko, Inna V., et al.
Publicado: (2015)

Histone deacetylase inhibitors: a promising partner for MEK inhibitors in uveal melanoma?
por: Faião-Flores, Fernanda, et al.
Publicado: (2019)

Why do women with melanoma do better than men?
por: Smalley, Keiran SM
Publicado: (2018)

Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma
por: Koomen, John M., et al.
Publicado: (2011)

SinCHet: a MATLAB toolbox for single cell heterogeneity analysis in cancer
por: Li, Jiannong, et al.
Publicado: (2017)

Drepmel—A Multi-Omics Melanoma Drug Repurposing Resource for Prioritizing Drug Combinations and Understanding Tumor Microenvironment
por: Thompson, Zachary J., et al.
Publicado: (2022)

XL888 limits vemurafenib-induced proliferative skin events by suppressing paradoxical MAPK activation
por: Phadke, Manali, et al.
Publicado: (2015)

OTME-17. Single cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases
por: Smalley, Inna, et al.
Publicado: (2021)

HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma
por: Sriramareddy, Sathya Neelature, et al.
Publicado: (2022)

Acral melanoma: new insights into the immune and genomic landscape
por: Carvalho, Larissa Anastacio DaCosta, et al.
Publicado: (2023)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
por: Fedorenko, Inna V., et al.
Publicado: (2015)

LMD-03. Single cell analysis reveals how therapy remodels the tumor microenvironment in melanoma CNS metastases and uncovers a novel predictor of improved survival
por: Smalley, Inna, et al.
Publicado: (2021)

Metabolomics of primary cutaneous melanoma and matched adjacent extratumoral microenvironment
por: Taylor, Nicholas J., et al.
Publicado: (2020)

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
por: Law, Vincent, et al.
Publicado: (2021)

Editorial of Special Issue on Tumor Microenvironment and Drug Delivery
por: Gao, Huile, et al.
Publicado: (2020)

Notch Signaling in Breast Tumor Microenvironment as Mediator of Drug Resistance
por: Chimento, Adele, et al.
Publicado: (2022)

23. RETROSPECTIVE REVIEW OF ADULT PATIENTS WITH LEPTOMENINGEAL DISEASE SECONDARY TO MELANOMA AT MOFFITT CANCER CENTER: DIAGNOSIS, TREATMENT AND OUTCOMES
por: Pina, Yolanda, et al.
Publicado: (2020)

LPTO-03. IN-VITRO & IN-VIVO CULTURE OF PATIENT (PT) DERIVED CSF-CTCs IN LEPTOMENINGEAL DISEASE (LMDz) FROM MELANOMA TO IDENTIFY NOVEL TREATMENT STRATEGIES
por: Law, Vincent, et al.
Publicado: (2019)

DRUG PRESCRIPTIONS IN PSYCHIATRY
por: Channabasavanna, S.M.
Publicado: (1988)

Youth And Drug Abuse
por: Channabasavanna, S.M.
Publicado: (1985)

Beyond BRAF: where next for melanoma therapy?
por: Fedorenko, I V, et al.
Publicado: (2015)

THE NARCOTIC DRUGS ACT AND THE PSYCHIATRIST
por: Channabasavanna, S.M.
Publicado: (1986)

Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibition
por: Phadke, Manali, et al.
Publicado: (2017)

ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment
por: Liu, Jiye, et al.
Publicado: (2021)

Tumor Microenvironment and Metabolism
por: Yang, Li V.
Publicado: (2017)

BAP1 Loss Promotes Suppressive Tumor Immune Microenvironment via Upregulation of PROS1 in Class 2 Uveal Melanomas
por: Kaler, Christopher J., et al.
Publicado: (2022)

Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma
por: Piña, Yolanda, et al.
Publicado: (2019)

Anthelmintics V: Drugs, resistance, and vaccines
por: Aroian, Raffi V., et al.
Publicado: (2023)

New mechanisms of multidrug resistance: an introduction to the Cancer Drug Resistance special collection
por: Gottesman, Michael M., et al.
Publicado: (2023)

In Vivo Acute Toxicity Studies of Novel Anti-Melanoma Compounds Downregulators of hnRNPH1/H2
por: Velayutham, Sadeeshkumar, et al.
Publicado: (2023)

Exosomal transmission between macrophages and cancer cells: new insights to stroma-mediated drug resistance
por: Gil, Ziv
Publicado: (2018)

Purinergic signaling microenvironments: An introduction
por: Schwiebert, Erik M., et al.
Publicado: (2008)

Pancreatic CSCs and microenvironment
por: Ilmer, Matthias, et al.
Publicado: (2015)

The Tumor Microenvironment and Cancer
por: Chen, Zhen, et al.
Publicado: (2014)

Inflammation in the Tumor Microenvironment
por: Lin, Qing, et al.
Publicado: (2018)

Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance
por: Khalaf, Khalil, et al.
Publicado: (2021)

Therapeutically targeting tumor microenvironment–mediated drug resistance in estrogen receptor–positive breast cancer
por: Shee, Kevin, et al.
Publicado: (2018)

Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance
por: Maacha, Selma, et al.
Publicado: (2019)

Exosome secretion from hypoxic cancer cells reshapes the tumor microenvironment and mediates drug resistance
por: To, Kenneth K. W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_djsr9iqt1uctr2u4hqi8v2gou5